XML 55 R37.htm IDEA: XBRL DOCUMENT v3.25.1
Shareholders' Equity (Tables)
12 Months Ended
Dec. 31, 2024
Shareholders  
Schedule of Stock Options Stock options for the year ended December 31, 2024 under the Company’s plans are as follows:
   Number of
options
   Weighted
average
exercise
price
   Weighted
average
remaining
contractual
term
(in years)
   Aggregate
intrinsic
value
 
                 
Outstanding as of January 1, 2024   39,597    7.98    1.75    16 
Granted   112,028    10.01           
Outstanding as of December 31, 2024   151,625    9.48    7.43    437 
Vested and expected to vest at December 31, 2024   50,321    8.42    2.68    198 
Exercisable as of December 31, 2024   50,321    8.42    2.68    198 
Schedule of RSUs under the Company’s 2013 Share Option Plan RSUs for the year ended December 31, 2024 under the Company’s 2013 Share Option Plan and 2023 Equity Incentive Plan are as follows:
   Number of
RSUs
 
     
Outstanding as of January 1, 2024   1,320,530 
Granted   997,364 
Vested   (607,884)
Cancelled   (239,084)
Outstanding as of December 31, 2024   1,470,926 
Schedule of Department Allocation of Share-Based Compensation Charges The following table summarizes the allocation of the Company’s share-based compensation within the consolidated statements of income (loss):
   Year ended December 31, 
   2024   2023   2022 
             
Cost of revenues  $381   $440   $391 
Research and development, net   2,047    2,690    2,503 
Sales and marketing   2,024    1,819    1,386 
General and administrative   1,645    1,168    894 
   $6,097   $6,117   $5,174